Cancel
See Linkedin
Known information
- Authored a study on the clinical use of circulating-free DNA fragmentomic in monitoring minimal residual disease for patients with non-small-cell lung cancer
- Developed regularized Cox regression models for detecting high-risk patients post-surgery using whole-genome sequencing-based cell-free DNA fragment profiles
- Achieved a detection sensitivity of 78.3% for patients with recurrence using both fragmentomics and circulating mutation results
About Geneseeq
Geneseeq is a genomic testing company specializing in precision oncology, headquartered in Toronto and Nanjing, serving over 8,000 oncologists with a variety of genomic tests and supporting numerous translational research projects.
Report inaccurate information
